{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:47:27Z","timestamp":1791874047971,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Boehringer Ingelheim Ky, Helsinki, Finland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13300-026-01879-z","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T09:46:14Z","timestamp":1780739174000},"page":"1043-1065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of Patient Clusters with Distinct Disease Progression Patterns Utilizing a Nationwide Finnish Population with Type 2 Diabetes"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3811-569X","authenticated-orcid":false,"given":"Kim","family":"Nyg\u00e5rd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Ryh\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-8257","authenticated-orcid":false,"given":"Aaron","family":"Kortteenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajsa","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-9956","authenticated-orcid":false,"given":"Aino","family":"Vesikansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-8561","authenticated-orcid":false,"given":"Juha","family":"Meht\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirkka","family":"Koivusalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annakaisa","family":"Tirronen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-6194","authenticated-orcid":false,"given":"Eralda","family":"Asllanaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarmo","family":"Kaukua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5904-5954","authenticated-orcid":false,"given":"Sami","family":"Pakarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2727-8849","authenticated-orcid":false,"given":"Juha","family":"Tuominen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"1879_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas 2025 | 11th edition. 2025. https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/. Accessed 17 Mar 2026."},{"key":"1879_CR2","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46:S19\u201340.","journal-title":"Diabetes Care"},{"key":"1879_CR3","unstructured":"The Finnish Medical Society Duodecim. Type 2 diabetes. Current care guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Cardiac Society. (referred March 17, 2026). Available online at: www.kaypahoito.fi."},{"key":"1879_CR4","unstructured":"Jarvala T, Raitanen J, Rissanen P. Kansallinen diabetesohjelma DEHKO. Diabeteksen kustannukset Suomessa 1998\u20132007. Tampere: Suomen diabetesliitto; 2010."},{"key":"1879_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00125-020-05363-6","volume":"64","author":"O Kurkela","year":"2021","unstructured":"Kurkela O, Forma L, Ilanne-Parikka P, et al. Association of diabetes type and chronic diabetes complications with early exit from the labour force: register-based study of people with diabetes in Finland. Diabetologia. 2021;64:795\u2013804.","journal-title":"Diabetologia"},{"key":"1879_CR6","first-page":"13","volume":"2","author":"S Koski","year":"2018","unstructured":"Koski S, Ilanne-Parikka P, Kurkela O, et al. Diabeteksen kustannukset: lis\u00e4sairauksien ilmaantumisen puolittaminen toisi satojen miljoonien s\u00e4\u00e4st\u00f6t vuodessa. Diabetes ja L\u00e4\u00e4k\u00e4ri. 2018;2:13\u20137.","journal-title":"Diabetes ja L\u00e4\u00e4k\u00e4ri"},{"key":"1879_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","volume":"6","author":"E Ahlqvist","year":"2018","unstructured":"Ahlqvist E, Storm P, K\u00e4r\u00e4j\u00e4m\u00e4ki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1879_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68771-z","volume":"10","author":"L Kopitar","year":"2020","unstructured":"Kopitar L, Kocbek P, Cilar L, et al. Early detection of type 2 diabetes mellitus using machine learning-based prediction models. Sci Rep. 2020;10:11981.","journal-title":"Sci Rep"},{"key":"1879_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-021-00767-9","volume":"13","author":"L Fregoso-Aparicio","year":"2021","unstructured":"Fregoso-Aparicio L, Noguez J, Montesinos L, et al. Machine learning and deep learning predictive models for type 2 diabetes: a systematic review. Diabetol Metab Syndr. 2021;13:148.","journal-title":"Diabetol Metab Syndr"},{"key":"1879_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-021-00394-8","volume":"4","author":"M Ravaut","year":"2021","unstructured":"Ravaut M, Sadeghi H, Leung KK, et al. Predicting adverse outcomes due to diabetes complications with machine learning using administrative health data. npj Digit Med. 2021;4:1\u201312.","journal-title":"npj Digit Med"},{"key":"1879_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108316","volume":"36","author":"H Shao","year":"2022","unstructured":"Shao H, Shi L, Lin Y, et al. Using modern risk engines and machine learning\/artificial intelligence to predict diabetes complications: a focus on the BRAVO model. J Diabetes Complicat. 2022;36:108316.","journal-title":"J Diabetes Complicat"},{"key":"1879_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jbi.2018.06.001","volume":"83","author":"E Parimbelli","year":"2018","unstructured":"Parimbelli E, Marini S, Sacchi L, et al. Patient similarity for precision medicine: a systematic review. J Biomed Inform. 2018;83:87\u201396.","journal-title":"J Biomed Inform"},{"key":"1879_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2020.104268","volume":"143","author":"KD Silva","year":"2020","unstructured":"Silva KD, Lee WK, Forbes A, et al. Use and performance of machine learning models for type 2 diabetes prediction in community settings: a systematic review and meta-analysis. Int J Med Inf. 2020;143:104268.","journal-title":"Int J Med Inf"},{"key":"1879_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52023-5","volume":"14","author":"M Lugner","year":"2024","unstructured":"Lugner M, Rawshani A, Helleryd E, et al. Identifying top ten predictors of type 2 diabetes through machine learning analysis of UK Biobank data. Sci Rep. 2024;14:2102.","journal-title":"Sci Rep"},{"key":"1879_CR15","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3390\/jcm9072083","volume":"9","author":"H Tanabe","year":"2020","unstructured":"Tanabe H, Saito H, Kudo A, et al. Factors associated with risk of diabetic complications in novel cluster-based diabetes subgroups: a Japanese retrospective cohort study. J Clin Med. 2020;9:2083.","journal-title":"J Clin Med"},{"key":"1879_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S2213-8587(19)30087-7","volume":"7","author":"JM Dennis","year":"2019","unstructured":"Dennis JM, Shields BM, Henley WE, et al. Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol. 2019;7:442\u201351.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1879_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001506","volume":"8","author":"RM Anjana","year":"2020","unstructured":"Anjana RM, Baskar V, Nair ATN, et al. Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. BMJ Open Diabetes Res Care. 2020;8:e001506.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1879_CR18","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1007\/s00125-024-06248-8","volume":"67","author":"H Tanabe","year":"2024","unstructured":"Tanabe H, Sato M, Miyake A, et al. Machine learning-based reproducible prediction of type 2 diabetes subtypes. Diabetologia. 2024;67:2446\u201358.","journal-title":"Diabetologia"},{"key":"1879_CR19","unstructured":"Arffman M, Ilanne-Parikka P, Keskim\u00e4ki I, et al. FinDM database on diabetes in Finland. https:\/\/urn.fi\/URN:ISBN:978-952-343-492-9."},{"key":"1879_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0165025409343765","volume":"33","author":"N Ram","year":"2009","unstructured":"Ram N, Grimm KJ. Growth mixture modeling: a method for identifying differences in longitudinal change among unobserved groups. Int J Behav Dev. 2009;33:565\u201376.","journal-title":"Int J Behav Dev"},{"key":"1879_CR21","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/jamainternmed.2021.4945","volume":"181","author":"MC Wang","year":"2021","unstructured":"Wang MC, Shah NS, Carnethon MR, et al. Age at diagnosis of diabetes by race and ethnicity in the United States from 2011 to 2018. JAMA Intern Med. 2021;181:1537.","journal-title":"JAMA Intern Med"},{"key":"1879_CR22","doi-asserted-by":"publisher","first-page":"11784","DOI":"10.1038\/s41598-022-16135-0","volume":"12","author":"G H\u00f6skuldsd\u00f3ttir","year":"2022","unstructured":"H\u00f6skuldsd\u00f3ttir G, Franz\u00e9n S, Eeg-Olofsson K, et al. Risk trajectories of complications in over one thousand newly diagnosed individuals with type 2 diabetes. Sci Rep. 2022;12:11784.","journal-title":"Sci Rep"},{"key":"1879_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pcd.2021.12.012","volume":"16","author":"K Mets\u00e4rinne","year":"2022","unstructured":"Mets\u00e4rinne K, Pietil\u00e4 M, Kantola I, et al. The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: a cross-sectional chart review study (STONE HF). Prim Care Diabetes. 2022;16:135\u201341.","journal-title":"Prim Care Diabetes"},{"key":"1879_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17:83.","journal-title":"Cardiovasc Diabetol"},{"key":"1879_CR25","first-page":"88","volume":"21","author":"RJ Middleton","year":"2006","unstructured":"Middleton RJ, Foley RN, Hegarty J, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2006;21:88\u201392.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"1879_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pcd.2014.06.001","volume":"9","author":"K Mets\u00e4rinne","year":"2015","unstructured":"Mets\u00e4rinne K, Br\u00f6ijersen A, Kantola I, et al. High prevalence of chronic kidney disease in Finnish patients with type 2 diabetes treated in primary care. Prim Care Diabetes. 2015;9:31\u20138.","journal-title":"Prim Care Diabetes"},{"key":"1879_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.pcd.2023.10.001","volume":"17","author":"K Mets\u00e4rinne","year":"2023","unstructured":"Mets\u00e4rinne K, Pietil\u00e4 M, Kantola I, et al. Chronic kidney disease stage is associated with the number of risk factors in type 2 diabetes patients (STages Of NEphropathy in type 2 diabetes and Heart Failure - STONE HF). Prim Care Diabetes. 2023;17:632\u20138.","journal-title":"Prim Care Diabetes"},{"key":"1879_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpbup.2024.100141","volume":"5","author":"M Khalifa","year":"2024","unstructured":"Khalifa M, Albadawy M. Artificial intelligence for diabetes: enhancing prevention, diagnosis, and effective management. Comput Methods Progr Biomed Update. 2024;5:100141.","journal-title":"Comput Methods Progr Biomed Update"},{"key":"1879_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17249523","volume":"17","author":"A Sarr\u00eda-Santamera","year":"2020","unstructured":"Sarr\u00eda-Santamera A, Orazumbekova B, Maulenkul T, et al. The identification of diabetes mellitus subtypes applying cluster analysis techniques: a systematic review. Int J Environ Res Public Health. 2020;17:9523.","journal-title":"Int J Environ Res Public Health"},{"key":"1879_CR30","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022.","DOI":"10.1007\/s00125-022-05787-2"},{"key":"1879_CR31","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12875-022-01889-3","volume":"23","author":"NA Nazu","year":"2022","unstructured":"Nazu NA, Wikstr\u00f6m K, Lamidi M-L, et al. Mode of treatments and achievement of treatment targets among type 2 diabetes patients with different comorbidities \u2013 a register-based retrospective cohort study in Finland. BMC Prim Care. 2022;23:278.","journal-title":"BMC Prim Care"},{"key":"1879_CR32","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","volume":"404","author":"B Zhou","year":"2024","unstructured":"Zhou B, Rayner AW, Gregg EW, et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404:2077\u201393.","journal-title":"Lancet"},{"key":"1879_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afae259","volume":"53","author":"J Bolt","year":"2024","unstructured":"Bolt J, Carvalho V, Lin K, et al. Systematic review of guideline recommendations for older and frail adults with type 2 diabetes mellitus. Age Ageing. 2024;53:afae259.","journal-title":"Age Ageing"},{"key":"1879_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255\u2013323.","journal-title":"Eur Heart J"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01879-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01879-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01879-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:08:08Z","timestamp":1784624888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01879-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1879"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01879-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Annakaisa Tirronen, Eralda Asllana, and Jarmo Kaukua are employees of Boehringer Ingelheim Ky and B.V. Aino Vesikansa, Mirkka Koivum\u00e4ki, and Juha Meht\u00e4l\u00e4 are employees of MedEngine Oy. Kim Nyg\u00e5rd, Riitta Ryh\u00e4nen, Aaron Kortteenniemi, Kajsa J\u00e4rvinen, Sami Pakarinen, and Juha Tuominen have nothing to disclose. The authors meet the criteria for authorship as recommended by the ICMJE. The authors did not receive payment related to the development of the manuscript. Anniina Snellman, PhD, and Harlan Barker, MSc, of MedEngine Oy provided writing assistance, which was contracted and funded by Boehringer Ingelheim.\u200b Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. The study was supported and funded by Boehringer Ingelheim.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Finnish data Permit Authority, Findata. No ethics approval or informed consent from the patients included in the study cohort was required by the Finnish legislation (Act on the Secondary Use of Health and Social Data (552\/2019) by the Ministry of Social Affairs and Health), as the persons were not contacted, and the study did not affect the treatment of patients. The study was conducted in accordance with the Helsinki Declaration of 1975, Good Pharmacoepidemiology Practices, and Data Protection Directive.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}